Latest news with #KevinChin
Business Wire
18 hours ago
- Business
- Business Wire
BitGo Enters Strategic Partnership with VivoPower to Facilitate its Initial $100 Million XRP Acquisition for Treasury Strategy
NEW YORK--(BUSINESS WIRE)--BitGo, the leading infrastructure provider of digital asset solutions, and VivoPower International PLC (Nasdaq: VVPR, 'VivoPower'), a publicly traded company that recently announced transition to an XRP focused treasury and decentralized finance solutions company, today announced a strategic partnership. VivoPower, having successfully raised $121 million, will leverage BitGo as an exclusive over-the-counter (OTC) trading desk to acquire XRP for its initial $100 million acquisition of XRP tokens. VivoPower will exclusively leverage BitGo for both the trading of its XRP holdings through BitGo's 24/7/365 OTC trading desk and holding of its assets through BitGo's best-in-class custody platform. As a result, VivoPower is expected to benefit from BitGo's liquidity, robust execution capabilities, and secure cold storage infrastructure. Kevin Chin, Executive Chairman and CEO of VivoPower, said: 'VivoPower is committed to driving value for our shareholders by building out a leading digital asset treasury strategy—a mission we plan to accomplish through partnerships with best-in-class digital asset leaders like BitGo. BitGo's track record, combined with its institutional-grade, secure-by-design custodial and trading infrastructure, makes them the clear choice to execute and safeguard our treasury allocation.' Mike Belshe, CEO of BitGo, said: 'VivoPower's commitment to digital assets is a testament to the institutional momentum building around our ecosystem. We are proud to provide the comprehensive platform that companies like VivoPower need to enter the digital asset space with confidence—from seamless execution to industry-leading custody.' The partnership underscores BitGo's growing position not only as a trusted custodian, but also as a premier trading partner for institutions executing large block trades. BitGo's OTC desk enables efficient access to deep, global liquidity pools and discreet execution of high-volume trades, all within a secure and compliant environment. VivoPower has filed a registration statement (including a prospectus) with the U.S. Securities and Exchange Commission (the 'SEC') for a public offering of its ordinary shares. Before you invest in the public offering, you should read the prospectus in that registration statement and other documents VivoPower has filed with the SEC for more complete information about the issuer and the public offering. You may get these documents for free by visiting EDGAR on the SEC Web site at Alternatively, VivoPower or Chardan, the placement agent for the public offering, will arrange to send you the prospectus if you request it by emailing shareholders@ or prospectus@ About BitGo BitGo is the leading infrastructure provider of digital asset solutions, delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. Since our founding in 2013, we have focused on enabling our clients to securely navigate the digital asset space. With a large global presence through multiple regulated entities, BitGo serves thousands of institutions, including many of the industry's top brands, exchanges, and platforms, as well as millions of retail investors worldwide. As the operational backbone of the digital economy, BitGo handles a significant portion of Bitcoin network transactions and is the largest independent digital asset custodian, and staking provider, in the world. For more information, visit About VivoPower VivoPower International PLC (NASDAQ: VVPR) is undergoing a strategic transformation into the world's first XRP-focused digital asset enterprise. The Company's new direction centers on the acquisition, management, and long-term holding of XRP digital assets as part of a diversified digital treasury strategy. Through this shift, VivoPower aims to contribute to the growth and utility of the XRP Ledger (XRPL) by supporting decentralized finance (DeFi) infrastructure and real-world blockchain applications. Originally founded in 2014 and listed on Nasdaq since 2016, VivoPower operates with a global footprint spanning the United Kingdom, Australia, North America, Europe, the Middle East, and Southeast Asia. An award-winning global sustainable energy solutions B Corporation, VivoPower has two business units, Tembo and Caret Digital. Tembo is focused on electric solutions for off-road and on-road customized and ruggedized fleet applications as well as ancillary financing, charging, battery and microgrids solutions. Caret Digital is a power-to-x business focused on the highest and best use cases for renewable power, including digital asset mining. Forward-Looking Statements This communication includes certain statements that may constitute 'forward-looking statements' for purposes of the U.S. federal securities laws. Forward-looking statements include, but are not limited to, statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about the achievement of performance hurdles, or the benefits of the events or transactions described in this communication and the expected returns therefrom. These statements are based on VivoPower's management's current expectations or beliefs and are subject to risk, uncertainty, and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive and/or regulatory factors, and other risks and uncertainties affecting the operation of VivoPower's business. These risks, uncertainties and contingencies include changes in business conditions, fluctuations in customer demand, changes in accounting interpretations, management of rapid growth, intensity of competition from other providers of products and services, changes in general economic conditions, geopolitical events and regulatory changes, and other factors set forth in VivoPower's filings with the United States Securities and Exchange Commission. The information set forth herein should be read in light of such risks. VivoPower is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements whether as a result of new information, future events, changes in assumptions or otherwise.
BusinessToday
22-05-2025
- Business
- BusinessToday
Taliworks Delivers Strong 1Q Performance With 12.8% Revenue Growth
Taliworks Corporation Bhd, a prominent Malaysian infrastructure and utilities provider, has reported a solid first-quarter performance for the financial year ending Dec 31, 2025 (1Q25), buoyed by robust contributions from its construction and renewable energy segments. The group posted a profit after tax of RM12.9 million, on the back of RM105.3 million in revenue, marking a 12.8% year-on-year (YoY) increase. The rise was largely attributed to the sustained construction progress on Phase 1, Packages 2 and 3 of the Sungai Rasau Water Supply Scheme, which drove construction segment revenue from RM11.8 million in 1Q24 to RM27.9 million in the current quarter. Revenue from the group's renewable energy (RE) segment climbed 13.6% YoY to RM7.5 million, fuelled by an 11.4% increase in solar energy output following the replacement of solar panels across all its photovoltaic plants. This reflects the group's growing momentum in clean energy, positioning it as a future growth pillar. 'Our water treatment, supply, and toll highway operations remain the bedrock of our performance,' said Executive Director Kevin Chin. 'However, we're pleased with the continued traction in our renewable energy business and the contribution from construction, both of which align with our strategy to diversify and scale high-impact infrastructure investments.' Chin added that Taliworks remains focused on expanding its infrastructure and RE footprint while maintaining cost discipline across all segments. 'To support long-term growth, we are actively seeking new opportunities to expand our construction order book and optimise operational efficiency,' Chin noted. In line with its commitment to shareholder returns, Taliworks declared a first interim single-tier dividend of 0.5 sen per share, amounting to RM10.08 million, payable on June 30, 2025. Based on the closing price of RM0.68 on May 19, 2025, the trailing 12-month dividend yield stands at an attractive 5.9%. Related
Yahoo
08-05-2025
- Business
- Yahoo
Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer
STARt-002 is a Phase 1b/2 clinical study assessing invikafusp alfa in combination with Gilead's Trodelvy® for HR+/HER2- and TNBC breast cancer patients across leading U.S. and Canadian breast cancer centers CAMBRIDGE, Mass., May 8, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to precision T cell activation, today announced that the first patient has been dosed in its STARt-002 clinical trial. The Phase 1b/2 study evaluates the safety and efficacy of Marengo's lead clinical T cell agonist in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead's approved TROP2-directed antibody-drug conjugate (ADC), in patients with metastatic breast cancer (mBC). "The growing body of evidence supporting combinations of ADCs and immunotherapies is encouraging, including the recent success of the ASCENT-04 trial combining sacituzumab govitecan with pembrolizumab in metastatic TNBC," said Steven Isakoff, M.D., Ph.D., Medical Oncologist and Director of Breast Cancer Clinical Research at Massachusetts General Hospital. "Invikafusp alfa is a novel bi-specific immunotherapy designed as a dual T cell agonist, and the recent AACR presentation highlighting its single-agent activity in PD-1 resistant tumors is particularly compelling. Coupled with preclinical evidence of efficacy in breast cancer models, this combination with an ADC offers a promising and innovative approach to expanding immunotherapy options for patients with both HR+/HER2- and triple-negative breast cancers." STARt-002 (NCT06827613) is a Phase 1b/2 trial, beginning with a run-in phase to determine the optimal tolerated combined dose of the two agents, followed by dose expansion in two patient cohorts: metastatic triple-negative breast cancer (mTNBC) and hormone receptor-positive, HER2-negative (HR+/HER2−) metastatic breast cancer. The study is currently enrolling patients at three leading North American cancer centers: Massachusetts General Hospital, Sarah Cannon Research Institute, and Princess Margaret Cancer Centre, with additional sites expected to join soon. "As presented in recent SITC, EMSO IO and AACR meetings, invikafusp clearly demonstrates promising monotherapy activity in PD-1 resistant tumors including MSS CRC and PD-1 negative NSCLC," said Kevin Chin, M.D., Chief Medical Officer of Marengo Therapeutics. "These data reinforce our belief that invikafusp could serve as a best-in-class immunotherapy backbone for multiple tumor types, particularly when paired with ADCs in immunologically cold tumors such as breast cancer. We are honored to partner with world-class clinical investigators to explore this promising combination for patients with high unmet needs." About Marengo Therapeutics Marengo Therapeutics, Inc. is a clinical-stage biotechnology company developing a first-in-class pipeline of novel TCR-targeting antibodies designed to selectively modulate disease-driving and protective T cell subsets. With its proprietary STAR™, TriSTAR™, and MSTAR™ platforms, Marengo is advancing precision immunotherapies that harness the body's T cell repertoire to provide durable responses against cancer and autoimmune diseases. Learn more at About the STAR™ Platform Marengo's STAR™ (Selective T cell Activation Repertoire) platform is a proprietary multispecific antibody-fusion technology targeting germline-encoded TCR Vβ regions fused with T cell co-stimulatory domains. This novel approach enables non-clonal activation and selective expansion of tumor-reactive T cells, driving durable anti-tumor immune responses. About Invikafusp Alfa (STAR0602) Invikafusp alfa (STAR0602) is the first clinical candidate emerging from Marengo's STAR™ platform. It selectively targets a common, tumor-associated Vβ T cell subset and combines non-clonal TCR activation with T cell co-stimulation in a single molecule. This unique mechanism promotes the expansion of effector memory T cells with anti-tumor activity. Invikafusp alfa is currently being evaluated in a Phase I/II clinical trial as monotherapy (STARt-001 trial) and in combination (STARt-002 trial) settings. About the STARt-002 Trial STARt-002 (NCT06827613) is a Phase Ib/II, open-label, multicenter study investigating the combination of invikafusp alfa and sacituzumab govitecan in patients with unresectable, locally advanced, or metastatic breast cancer. The trial consists of a safety lead-in phase followed by two dose-expansion cohorts: one in triple-negative breast cancer (mTNBC) and one in HR+/HER2− metastatic breast cancer. More information is available at Media Contact:Peg Rusconi | Investor Contact:Svetlana Makhni | smakhni@ View original content to download multimedia: SOURCE Marengo Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
